185 related articles for article (PubMed ID: 32695875)
1. Autologous Transplantation Using Donor Leukocytes Loaded
Villa NY; Rahman MM; Mamola J; D'Isabella J; Goras E; Kilbourne J; Lowe K; Daggett-Vondras J; Torres L; Christie J; Appel N; Cox AL; Kim JB; McFadden G
Mol Ther Oncolytics; 2020 Sep; 18():171-188. PubMed ID: 32695875
[TBL] [Abstract][Full Text] [Related]
2. Transplantation of autologous bone marrow pre-loaded
Villa NY; Rahman MM; Mamola J; Sharik ME; de Matos AL; Kilbourne J; Lowe K; Daggett-Vondras J; D'Isabella J; Goras E; Chesi M; Bergsagel PL; McFadden G
Oncotarget; 2022; 13():490-504. PubMed ID: 35251496
[TBL] [Abstract][Full Text] [Related]
3. Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor.
Lilly CL; Villa NY; Lemos de Matos A; Ali HM; Dhillon JS; Hofland T; Rahman MM; Chan W; Bogen B; Cogle C; McFadden G
Mol Ther Oncolytics; 2017 Mar; 4():31-40. PubMed ID: 28345022
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.
Villa NY; Bais S; Chan WM; Meacham AM; Wise E; Rahman MM; Moreb JS; Rosenau EH; Wingard JR; McFadden G; Cogle CR
Cytotherapy; 2016 Mar; 18(3):465-80. PubMed ID: 26857235
[TBL] [Abstract][Full Text] [Related]
5. Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer.
Villa NY; Franco LS; McFadden G
Methods Mol Biol; 2020; 2058():95-110. PubMed ID: 31486033
[TBL] [Abstract][Full Text] [Related]
6. Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma.
Christie JD; Appel N; Canter H; Achi JG; Elliott NM; de Matos AL; Franco L; Kilbourne J; Lowe K; Rahman MM; Villa NY; Carmen J; Luna E; Blattman J; McFadden G
Mol Ther Oncolytics; 2021 Sep; 22():539-554. PubMed ID: 34553039
[TBL] [Abstract][Full Text] [Related]
7. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.
Villa NY; Wasserfall CH; Meacham AM; Wise E; Chan W; Wingard JR; McFadden G; Cogle CR
Blood; 2015 Jun; 125(24):3778-88. PubMed ID: 25904246
[TBL] [Abstract][Full Text] [Related]
8. Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease.
Villa NY; McFadden G
Curr Pathobiol Rep; 2018; 6(4):247-263. PubMed ID: 30595970
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.
Madlambayan GJ; Bartee E; Kim M; Rahman MM; Meacham A; Scott EW; McFadden G; Cogle CR
Leuk Res; 2012 May; 36(5):619-24. PubMed ID: 22341701
[TBL] [Abstract][Full Text] [Related]
10. Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma.
Christie JD; Appel N; Zhang L; Lowe K; Kilbourne J; Daggett-Vondras J; Elliott N; Lucas AR; Blattman JN; Rahman MM; McFadden G
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053501
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice.
Bartee E; Bartee MY; Bogen B; Yu XZ
Mol Ther Oncolytics; 2016; 3():16032. PubMed ID: 27933316
[TBL] [Abstract][Full Text] [Related]
12. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus.
Bartee E; Chan WM; Moreb JS; Cogle CR; McFadden G
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1540-51. PubMed ID: 22516053
[TBL] [Abstract][Full Text] [Related]
13. Myxoma and vaccinia viruses bind differentially to human leukocytes.
Chan WM; Bartee EC; Moreb JS; Dower K; Connor JH; McFadden G
J Virol; 2013 Apr; 87(8):4445-60. PubMed ID: 23388707
[TBL] [Abstract][Full Text] [Related]
14. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
[TBL] [Abstract][Full Text] [Related]
15. Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.
Weng M; Gong W; Ma M; Chu B; Qin Y; Zhang M; Lun X; McFadden G; Forsyth P; Yang Y; Quan Z
Mol Cancer; 2014 Apr; 13():82. PubMed ID: 24725816
[TBL] [Abstract][Full Text] [Related]
16. Dual-Armed Oncolytic Myxoma Virus Encoding IFN-γ and CD47 Promotes Lymphocyte Infiltration and Tumor Suppression of Syngeneic Murine Melanoma.
Woo JK; Kim TG; Im NY; Son KY; Cho M; Jeong YJ; Hong JI; Kang B; Enkhtaivan G; Cho NH; Alain T; Park DG; Lee YS
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835397
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus.
Rahman MM; Madlambayan GJ; Cogle CR; McFadden G
Cytokine Growth Factor Rev; 2010; 21(2-3):169-75. PubMed ID: 20211576
[TBL] [Abstract][Full Text] [Related]
18. The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma.
Stewart G; Chantry A; Lawson M
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830842
[TBL] [Abstract][Full Text] [Related]
19. Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model.
Nounamo B; Liem J; Cannon M; Liu J
Mol Ther Oncolytics; 2017 Sep; 6():90-99. PubMed ID: 28875159
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]